About The Study: By assigning lower atherosclerotic cardiovascular disease risk predictions, application of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million U.S. adults.
About The Study: By assigning lower atherosclerotic cardiovascular disease risk predictions, application of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million U.S. adults.
Corresponding Author: To contact the corresponding author, Arjun K. Manrai, Ph.D., email Arjun_Manrai@hms.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.12537)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Cite Scienmag News
Ophelia Keating. (July 29, 2024). Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. Scienmag. https://scienmag.com/projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations/
Ophelia Keating. "Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations." Scienmag, 29 July 2024, https://scienmag.com/projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations/. Accessed 3 September 2026.
Ophelia Keating. "Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations." Scienmag. July 29, 2024. https://scienmag.com/projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations/
